



# **Transcript Details**

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/advanced-endometrial-carcinoma-a-look-into-care-considerations/16275/

#### ReachMD

www.reachmd.com info@reachmd.com (866) 423-7849

Advanced Endometrial Carcinoma: A Look Into Care Considerations

### ReachMD Announcer:

You're listening to a ReachMD medical industry feature, titled "Advanced Endometrial Carcinoma: A Look into Care Considerations".

#### Voiceover:

This presentation has been created and paid for by Merck. The information in this presentation is intended for healthcare professionals in the United States and its territories, including Puerto Rico.

# Medical Oncologist:

Tina, do you have a moment to discuss the treatment plan for the patient in room 7?

# **Nurse Practitioner:**

Hi Dr. Jones. Yes, how can I help?

### Medical Oncologist:

You may remember Linda; she was here a few months ago... age 57, diagnosed with stage IVB endometrial carcinoma with endometrioid histology and lung metastases.

# Nurse Practitioner:

Oh yes, I remember her well! She was so sweet and was excited about her first grandchild being born. Do you have an update on Linda?

### Medical Oncologist:

We started treatment with carboplatin and paclitaxel 3 months ago. Unfortunately, a CT shows disease progression with worsening lung metastases. She is not eligible for curative surgery or radiation. I see in her chart that she has an ECOG of 0. Comorbidities include obesity and hypertension.

#### **Nurse Practitioner:**

Let's review her biomarker status. That might help us understand her treatment options.

# Medical Oncologist:

Yes, that's a great idea. I would typically treat a patient like Linda with chemotherapy, but I would like the multi-disciplinary team to weigh in to see if she may be eligible for a biomarker-directed treatment option.

# **Nurse Practitioner:**

I'll look forward to hearing the outcome of the team's discussion so we can move forward to the next steps of Linda's treatment plan.

# Voiceover:

Explore more about a biomarker-directed treatment option for patients with certain types of advanced endometrial carcinoma.





Learn more at <a href="IsLindaEligible.com">IsLindaEligible.com</a>.

# ReachMD Announcer:

This program was sponsored by Merck and Eisai. If you missed any part of this discussion, visit Industry Features on ReachMD.com, where you can Be Part of the Knowledge.

Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-END-00435 02/24